Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis - Wikidata - wikimedia - TriplyDB

Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis

Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis

http://www.wikidata.org/entity/Q35127833

about

Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Pharmacokinetics and tissue distribution of anidulafungin in rats.Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia Antifungal pharmacokinetics and pharmacodynamics Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicans.Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.Anidulafungin--state of affairs from a clinical perspective.Anidulafungin in the treatment of invasive fungal infections.Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.Anidulafungin treatment of candidal central nervous system infection in a murine model Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility.Anidulafungin: a novel echinocandin for candida infections.Paradoxical echinocandin activity: a limited in vitro phenomenon?Echinocandin pharmacodynamics: review and clinical implications.Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia.Anidulafungin and its role in candida infections In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels.Pharmacodynamics of the Long Acting Echinocandin, CD101, in the Neutropenic Invasive Candidiasis Murine Model Using an Extended Interval Dosing Design.A quantitative systems pharmacology (QSP) model for Pneumocystis treatment in mice In silico-derived bedside formula for individualized micafungin dosing for obese patients in the age of deterministic chaos

P2860

Q27318203-F009B1A8-A14D-4DFA-B6E2-28B4FCC00B7C Q33490772-025E42D4-F5CD-4BCF-ABEE-DB8D0D8991C3 Q33876423-74741D85-C351-4196-AB15-22BB2C36EE07 Q34591184-42FB2DE3-D363-4E3C-9113-A6FB79D25065 Q35105763-4A8A07AD-F2F7-4D64-B24A-848DA14AAFF7 Q35270758-27D5E56D-37A7-40FC-8B80-43FDEFC40EE1 Q35647785-1F31DF48-D918-4B95-A3E1-F5011F7BCBC3 Q35663841-4D603F67-E84A-4A29-9E3F-430404375D9D Q35806170-AC173D49-B480-4E22-9441-EC3BB895F4CB Q35959484-A851AFC3-8B2F-4C52-8ADC-3743FE06E814 Q36425025-093F5DAE-96C0-4CAA-8D9D-1F485CBA4EB2 Q36482785-FF79A22F-7866-438C-BBD0-E47102D1FCE7 Q36505281-540712A2-D832-452E-8B21-3503F8BC802C Q36774257-544A334B-44E0-4375-B328-D816A13535C5 Q36822941-75571F5A-0CA0-464A-B310-8EDB6BE04900 Q36845482-849A1683-4BB5-4BE2-89E6-B0CEC354EA45 Q37274734-4961EED2-C3D0-4028-BADB-6131FE014ED6 Q37291442-8A3E0905-7775-4536-B555-F24A90C58620 Q37345790-F22F4E24-FB8D-4EDB-B5C5-6F6094890FAC Q37405284-4955F7A4-85E5-499F-A461-7F485E744939 Q37718385-33ECD6FC-94DD-485C-8DA6-422C0CF52155 Q37720794-8B8D7A88-A48F-47F4-804B-AC60AFD76BE8 Q37785979-5AF958F0-CB91-417E-8DC5-BBF7B75E7EEF Q38535647-1D5A2BED-CF7B-4ED4-A610-54C34234EFCE Q42731827-D8057533-E555-42BC-B464-D25A9979E124 Q42845954-61BFA8F0-1849-42B8-B270-423DE86053B0 Q43153532-9B0E9A07-1160-44D9-81AE-3DAF2F861970 Q46248423-8FAD6ABE-060B-4750-A782-4F29818BD1F5 Q57175587-74FD8720-809A-48A7-AC81-CC7E7741A931 Q58033439-2AAB8C0B-0CB8-418D-822F-9EB23DB54959

P2860

Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis

http://www.wikidata.org/entity/Q35127833

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Anidulafungin pharmacokinetics ...... with disseminated candidiasis

@ast

Anidulafungin pharmacokinetics ...... with disseminated candidiasis

@en

type

label

Anidulafungin pharmacokinetics ...... with disseminated candidiasis

@ast

Anidulafungin pharmacokinetics ...... with disseminated candidiasis

@en

prefLabel

Anidulafungin pharmacokinetics ...... with disseminated candidiasis

@ast

Anidulafungin pharmacokinetics ...... with disseminated candidiasis

@en

P1433

Q35127833-C0DF7CBF-824D-4958-9ABC-014B1158AF9E

P1476

Q35127833-A20B8CA8-0138-4D18-BE79-D51ED643F4D6

P2093

Q35127833-188AC5F7-4626-432D-8734-1F545B6F738F

Q35127833-1F0E2645-C61F-4CA0-B82F-6AE07C6A1F0A

Q35127833-6B7CE1EF-8917-4ED7-8E87-197744BC7FA1

Q35127833-8E7B0924-FB41-4230-AB37-CE2B48435AB5

Q35127833-A7064FC3-FEDB-48C9-8132-18C14D413C8B

Q35127833-EA2B8C86-BD7C-46DD-B748-15414C7C92E6

P2860

Q35127833-14075C38-E043-4E7D-99F5-153EF17DBC13

Q35127833-1852D5FE-9D38-41F2-A4D9-0D3ABE019A4E

Q35127833-38C78E5A-3058-4809-AB58-4EFAA297586B

Q35127833-443454FE-6C89-4D10-90C4-2F2756A6B17A

Q35127833-49E89D83-8C5C-42C4-A8C3-19EAFB22E5C4

Q35127833-664501FE-21E3-4D02-82CA-F7BEB0F0483A

Q35127833-75E5BB29-5B60-414A-9056-09CB34F09817

Q35127833-95495130-8AC6-48F2-94AB-27B9628E9340

Q35127833-A8288A15-BF14-415C-A6D0-4B162511B85B

Q35127833-B7883E70-F638-4EB8-B837-772372A5A531

P304

Q35127833-3E25250E-F693-4B77-BF11-CE98906C1B7D

P31

Q35127833-8E81F5FA-45DB-4A41-A308-31A078421EB0

P356

Q35127833-4071167A-F336-4E48-ACA6-1CCA53CFC86B

P407

Q35127833-ADF417F6-AB1C-4AF4-A952-CE2D1E2524E0

P433

Q35127833-0C30B133-4093-4E13-949D-616DB72A93EE

P478

Q35127833-EE2DB1C2-C862-45EB-BEF6-C136DE463818

P50

Q35127833-6591F113-3393-40B1-8DBA-6B8E133436A7

P577

Q35127833-300C9A5E-D179-40C5-AD3C-D8267CDB6C7B

P5875

Q35127833-06007ED2-B261-4BC9-B7D0-CABBE249AACB

P698

Q35127833-1E7D07B5-AE3B-4DD7-91C8-5F0B48034055

P932

Q35127833-D06C9ED6-7596-470A-91D6-1C088125C90D

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Anidulafungin pharmacokinetics ...... with disseminated candidiasis

@en

P2093

Arnold Louie

http://www.w3.org/2001/XMLSchema#string

George L Drusano

http://www.w3.org/2001/XMLSchema#string

Lei Ma

http://www.w3.org/2001/XMLSchema#string

Mark R Deziel

http://www.w3.org/2001/XMLSchema#string

Michael F Drusano

http://www.w3.org/2001/XMLSchema#string

Weiguo Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

Mortality and costs of acute renal failure associated with amphotericin B therapy.

Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.

Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling

Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice.

Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility.

Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.

Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.

Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

P304

3695-3700

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00507-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-09-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6836430

http://www.w3.org/2001/XMLSchema#string

P698

16954319

http://www.w3.org/2001/XMLSchema#string

P932

1635198

http://www.w3.org/2001/XMLSchema#string